Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

EGF 105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (T) based systemic therapy and cranial radiotherapy (RT)

Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Laessig D, Roche H, Zembryki D, Oliva CR, Winer EP. EGF 105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (T) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol. 2007; 25(18S):abstract 1012.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.